ODEVIXIBAT | N215498 | IPSEN BIOPHARMACEUTICALS INC
| Patent # | Expiration | PED | Drug Substance | Drug Product | Use Code | Delist |
|---|---|---|---|---|---|---|
| 9694018 | Mar 18, 2034 | — | — | — | — | |
| 10011633 | Nov 8, 2031 | — | — | — | — | |
| 10093697 | Nov 8, 2031 | — | — | — | — | |
| 10487111 | Nov 8, 2031 | — | — | — | — | |
| 10975046 | Jun 20, 2039 | — | Yes | — | — | — |
| 10981952 | Nov 8, 2031 | — | — | — | — | |
| 11365182 | Jun 20, 2039 | — | — | — | — | |
| 11583539 | Nov 12, 2041 | — | — | — | — | |
| 11732006 | Nov 8, 2031 | — | — | — | — | |
| 11801226 | Jun 20, 2039 | — | — | Yes | — | — |
| 11802115 | Jun 20, 2039 | — | — | Yes | — | — |
| 12091394 | Jun 20, 2039 | — | Yes | — | — | — |
| 12187812 | Nov 8, 2031 | — | — | — | — | |
| 12447156 | Nov 12, 2041 | — | — | — | — | |
| 12508234 | Jun 20, 2039 | — | — | — | — | |
| 12545705 | Nov 8, 2031 | — | — | — | — |
| Code | Date | Status |
|---|---|---|
| I-918 | Jun 13, 2026 | Expired |
| NCE | Jul 20, 2026 | < 1 year |
| ODE-363 | Jul 20, 2028 | Active |
| ODE-436 | Jun 13, 2030 | Active |
Patent US 9694018 covering Odevixibat (Bylvay) was extended, with the expiration date moving from Nov 2031 to Mar 2034.
Old: Nov 8, 2031
New: Mar 18, 2034
BYLVAY (odevixibat) patent 9,694,018 expiration date extended from Nov 2031 to Mar 2034.
Old: Nov 8, 2031
New: Mar 18, 2034
Ipsen's listed patent 9,694,018 for BYLVAY (odevixibat) was updated to extend patent expiration from Nov 2031 to Mar 2034.
Old: Nov 8, 2031
New: Mar 18, 2034
BYLVAY (odevixibat) patent 9,694,018 expiration date extended from Nov 2031 to Mar 2034 in Orange Book.
Old: Nov 8, 2031
New: Mar 18, 2034